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Emergence of HybridModels of Genetic Testing
Beyond Direct-to-Consumer or Traditional Labs
Historically, genetic evaluation has been dominated by
aclinician-centrictraditionalmodelinwhichapatient’sphy-
sicianhadthecentral responsibility for testing,suchasor-
deringthetestandcommunicatingtheresults.Conversely,
in the direct-to-consumer (DTC) model, consumers are
moreempoweredbecausetheycanordertheirowntests,
obtainsamplesusinghometestkits,andreceivetheresults
directly fromthe laboratoryorcompanythatprovidesthe
test.TheDTCmarkethasexpandedsubstantially, reignit-
ing controversies over the potential implications of DTC
testing for genetic health risks.1
However, little attention has been paid to the emer-
genceandeffectofnewmodelsofgenetic testingthat fall
in amiddle ground between the DTCmodel and the tra-
ditionalmodel, which is also known as the hybrid labora-
torymodel (eTable intheSupplement).Thismodel isahy-
brid because it is centric to both the consumer and the
clinician in that hybrid laboratories facilitate easier con-
sumer access, but a clinician (who may be the consum-
er’sregularphysicianoraphysicianprovidedfromthelabo-
ratory’s network) orders the test and returns the results.
Thismodel emerged for anumberof reasons. First, there
wasaperceivedneedtomaketestingmorefocusedonthe
consumer and easier to obtain than testing from tradi-
tional laboratories, while also providing medical-grade
testing so that the results canbeused for clinical decision
making, in contrast to the DTC model. Second, this ap-
proachpresentedaprofitopportunity for laboratoriesby
generating additional consumer demand via easier ac-
cessandanetworkofpartneringprescribers,whilesimul-
taneously addressing concerns about DTC testing.2
Hybrid laboratoriesarean increasingpartof themar-
ketplaceandtheir testingvolumeandrevenuehavebeen
rapidly increasing (eg, 1 company reported year-to-year
growth in volume and revenue of >100% from 2017 to
2018) and for the same period reported testing volume
hasgonefrom145000to292000withrevenueincreas-
ing from$68.2millionto$147.7million.3Although it isun-
clear what proportion of laboratories and testing vol-
ume or revenue fall into the 3 model types, at least 291
laboratories in theUnited States are performing genetic
testing.4 One large traditional laboratory recently re-
portedthat ithasconducted4milliontestssinceitsfound-
ing in 19915 and a hybrid laboratory reported it has con-
ducted 1.4million tests since its founding in 2004.6
Thedefinitionandrolesofthehybridmodelarepoorly
understood by consumers, clinicians, researchers, and
policymakers.Hybridmodelshaverarelybeenexamined
asadistinctentityandwhentheyhave,theyareusually la-
beled and studied as if theywere DTC laboratories even
thoughtheyarequitedifferent.Theemergenceofthehy-
brid model has significant implications for everyone in-
volvedingenetictesting,providingbothpotentialbenefits
such as improved access but also potential risks such as
lower testing quality or inappropriate test ordering.
AGap Between DTC and Traditional Models
The existence of DTC and traditional laboratorymodels,
which are at 2 ends of the spectrum, left a gap in the
middle of the spectrum.On the one hand, theDTC labo-
ratorymodel addresses a gap in consumer engagement.
It challenges the long-standing tenet exemplified by the
traditionalclinician-centric laboratorymodel:thatthetest-
ing process and decisions must be facilitated by a clini-
cian rather than the consumer. Testing is no longer con-
finedtopatientswhoareunder thecareof their clinician,
but is available to consumerswho are purchasing a con-
sumer good. The extraordinary growth of DTC genetic
testing suggests that consumers valuemore active roles
in testing. The hybrid model, by facilitating easier con-
sumer access, similarly addresses consumer desire for
more engagement and choice in genetic testing.
However, the hybrid model retains a key aspect of
the traditional model in that clinicians are still involved
in the process because they must order the tests and
communicate the results. The clinician who orders the
test can be the patient’s regular physician or, when re-
quested,manyhybrid laboratoriesprovideaccess to cli-
niciansvia third-partynetworks.Therearenodata in the
publicdomain fromhybrid laboratories that clarifywhat
percentage of tests ordered are from the consumer’s
regular physician vs from a consulting physician sug-
gestedby the hybrid laboratory. However, the required
clinician involvement enables hybrid laboratories to be
regulated in thesamewayas traditional laboratoriesand
thusprovidemedical-grade results.Thisaddressesagap
and key concern about theDTCmodel, inwhich results
are not certified for use in clinical decisionmaking. The
legal and regulatory status of physicians acting as con-
sultants for consumers who live in states in which they
do not have a license to practice remains unclear.
Thehybridmodelalsoaddressesthedesireofpatients
for lowerandmoretransparentprices. It isdifficulttocom-
pare test prices because they varyby laboratory, self-pay
priceor insurer reimbursement, andpatientpayment as-
sistanceprograms.However, ingeneral,prices forgenetic
testinghavedeclined(withmoregenesmeasuredfor the
sameor at a lower price)withDTC and hybrid laboratory
modelsat theforefrontof this trend.Testprices forbreast
cancerandrelatedcancer riskpanelsareagoodexample.
UntilaSupremeCourtdecisionin2013,MyriadGeneticshad
amonopolyon testing for2keymutations (BRCA1/2) and
charged approximately $4000 for this test. Current list
prices arenot available, but the2015 list prices for cancer
riskpanels(includingBRCA1/2andothergenes)from3tra-
ditional laboratories ranged from $3382 to $6040.7 In
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contrast,somehybridlaboratorieschargeanapproximateself-payprice
of$200foracancer riskpanel that includesBRCA1/2andothergenes.
Potential Benefits and Unintended Consequences
Therearenopublishedstudiescomparingthe3differentmodelstoas-
sesstheirbenefits, risks,andeffectsonpatientoutcomes.Bothpoten-
tialbenefitsandunintendedconsequencesexist(Box).Althoughstated
concernsmayreflectgeneralconcernsaboutgenetictestingratherthan
bespecifictothehybridmodel,theemergenceofthismodelhasheight-
ened concerns about issues such as the overuse of testing.
Consumersgenerallyhavealimitedunderstandingofgenetictest-
ing andpersonalizedmedicine. In 1 surveyof 1001USadults, 66%re-
portedthattheyhaveneverheardorreadanythingaboutpersonalized
orprecisionmedicine.8Itisthuslikelythatconsumersdonotunderstand
thedifferencesintestingapproachesacrosslaboratorymodels(eg,how
cancerrisktestresultsfromhybrid laboratoriesaredifferentthanthose
providedbyDTClaboratories).1 It isalsolikelythatclinicians’perceptions
ofthebenefitsandrisksvarywidely; therefore,awidevariabilityexists
whether theyorder testing fromhybridor traditional laboratories.
There are other challengeswith hybrid laboratories. Lower self-
pay prices may cause insurers to reduce their reimbursement rates,
orcausethemtoperceivegenetictestingasanover-the-counterprod-
uctthatdoesnotneedcoverage.Becauselow-incomeconsumersmay
not be able to afford a $200 test, theymaybe unable to obtain test-
ingifself-paymentbecomesthenorm.Laboratoriesatacademicmedi-
cal centers may not be able to match low prices at hybrid laborato-
ries, and the resulting reduced testing volumes could have negative
effects on their ability to fulfill their training and public service mis-
sions. More laboratories conducting testing may introduce addi-
tional variability in the quality and reporting of results, further con-
fusing consumers and physicians. In addition, the emergence of the
hybridmodel has heightened concerns about the overuse of testing
that does not improve health or personal outcomes.
Research and Policy Agenda
Theevolving landscaperequiresevidencesothat relevantpartiescan
make informeddecisions.Thehybridmodelcannotbeexaminedas if
itwasaDTCmodel, andwithin thehybridmodel, specific laboratories
mayhavevaryingcharacteristics.Consumersneedclearexplanations
of their choices, clinicians need an understanding of the advantages
andlimitationsofvariousmodels,andpolicymakersneedinformation
onthetrade-offsbetweencosts,benefits,andriskstocreate informed
regulationsandpolicies.Thehybridlaboratorymodelis likelytobecome
morecommonandthesemodelsportenda future inwhich themod-
elsat theextremesof thecontinuum—theDTCandtraditional labora-
torymodels—may increasinglymorph into hybridmodels.
In conclusion, the genetic testing landscape is rapidly chang-
ing. It is important for consumers, clinicians, policy makers, and
insurers to understand these changes, and recognize the implica-
tions of the hybrid laboratory model.
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Box. Potential Benefits and Concerns of a HybridModel
for Genetic Testing
Potential Benefits of HybridModel
• Greater access to testing for the consumer, particularly when the
test is not covered by insurance, when the consumer does not
have a regular clinician, when the consumer chooses not to use
the clinician to order testing, or when family members of the
affected individual also should be tested
• Potentially lower cost for the consumer
• Greater convenience for the consumerwhen he/she does not need
separate visits for sample collection, genetic counseling, or both
• Convenience for clinicians because of less paperwork if testing is
paid out of pocket and they do not need to request prior
authorization or meet other insurer requirements
Potential Concerns of HybridModel
• Removal of the testing process from in-house or traditional
laboratories may reduce continuity of care
• Patients may not follow clinician recommendations
• It can bemore difficult for consumers and clinicians to assess
laboratory offerings and quality given the increased choices
• Guidance and counseling provided by laboratory-provided
prescribers may not be as extensive as warranted, with concerns
that required clinician involvement can becomemore a formality
than an informed decision
• How these prescriber networks function is not well understood,
including how theymeet varying state requirements for who is
licensed to prescribe
• As with any commercial laboratory, hybrid laboratories are
motivated by profit
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